Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

11

Revenue 2017

AstraZeneca

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of AstraZeneca's 2013 sales performance.

Astra Zeneca

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation The European Medicines Agency (EMA) has granted AstraZeneca's (AZ) COVID-19 vaccine, Vaxzevria – ChAdOx1-S [Recombinant] – full Marketing Authorisation (MA) in the EU.

GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment

GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment The vaccine was well-tolerated and no safety concerns were observed. For the prevention of RSV disease in newborns and children, AstraZeneca and Sanofi’s Beyfortus (nirsevimab) was recommended for conditional

Alexion's Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Alexion's Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial Alexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) significantly reduced relapse risk in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) compared to an

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

AstraZeneca’s two advanced breast cancer trials meet primary endpoints Both trials showed significant improvement in progression-free survival. AstraZeneca (AZ) has announced positive high-level results from two individual advanced breast cancer trials evaluating both its next-generation oral selective

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer AstraZeneca’s Imjudo (tremelimumab) – an anti-CTLA4 antibody – in combination with Imfinzi (durvalumab) – an anti-PD-L1 antibody – has been approved by the US Food and Drug Administration (FDA) for the

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...